Background Increasing evidence supports that antibodies can protect against active
tuberculosis (TB) but knowledge of potentially protective antigens, especially in the airways …

The World Health Organization (WHO) herald of the “End TB Strategy” has defined goals
and targets for tuberculosis prevention, care, and control to end the global tuberculosis …

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb) that
sits in the top 10 leading causes of death in the world today and is the current leading cause …

Background A large, double-blind, randomised, placebo-controlled trial of repeat BCG found
49% efficacy against leprosy but no protection against tuberculosis after 6–9 years' follow-up …

The rise of antibiotic resistance has caused the prevention and treatment of bacterial
infections to be less effective. Therefore, researchers turn to nanomedicine for novel and …

Although tuberculosis (TB) remains one of the leading causes of death from an infectious
disease worldwide, the development of vaccines more effective than bacille Calmette …

Abstract The 2021 Global Vaccine and Immunization Research Forum highlighted the
considerable advances and recent progress in research and development for vaccines and …

In tuberculosis (TB) vaccine development, multiple factors hinder the design and
interpretation of the clinical trials used to estimate vaccine efficacy. The complex …

Vaccination strategies against mycobacteria, focusing mostly on classical T‐and B‐cells,
have shown limited success, encouraging the addition of alternative targets. Classically …

Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium tuberculosis
(Mtb), and its incidence and mortality are increasing. The BCG vaccine was developed in the …